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SYNOPSIS27
Objectives: To determine the prevalence of low inferred frequency HIV-1 transmitted28
drug resistance (TDR) in men who have sex with men (MSM) in the UK and their29
predicted effect on first-line therapy.30
31
Methods: The HIV-1 pol gene was amplified from 442 newly diagnosed MSM identified32
as likely recently infected by serological avidity testing in 2011 to 2013. The PCR33
products were sequenced by next generation sequencing with a mutation frequency34
threshold of >2% and TDR mutations defined according to the 2009 WHO surveillance35
drug resistance mutations (SDRM) list.36
37
Results: The majority (75.6%) were infected with subtype B and 6.6% with rare38
complex or unique recombinant forms. At mutation frequency threshold of >20%, 7.2%39
[5.0 – 10.1%] of the sequences had TDR and this doubled to 15.8% [12.6 – 19.6%] at40
>2% mutation frequency (p<0.0001). The majority (26/42; 62%) of low frequency41
variants were against protease inhibitors (PIs). The most common mutations detected at42
>20 and 2-20% mutation frequency differed for each drug class, these being: L90M43
(n=7) and M46IL (n=10) for PIs, T215rev (n=9) and D67GN (n=4) for nucleos(t)ide44
reverse transcriptase inhibitors (NRTIs), K103N (n=5) and K101E/G190E (n=2 each) for45
non-nucleoside RTIs (NNRTIs), respectively. Combined TDR was more frequent in46
subtype B than non-B (OR=0.38; 95%CI=0.17-0.88; p=0.024) and had minimal predicted47
effect on recommended first-line therapies.48
49
Conclusions: The data suggest differences in the types of low frequency compared to50
majority TDR variants that requires a better understanding of the origins and clinical51
significance of low frequency variants. This will better inform diagnostic and treatment52
strategies.53
54
INTRODUCTION55
Drug resistance mutations identified in newly diagnosed, treatment-naïve patients are56
presumed to be a result of the transmission of drug resistant variants. Transmitted drug57
resistance (TDR) can limit the treatment options available to newly diagnosed HIV-158
positive patients and is associated with an increased risk of virologic failure.1, 2 The59
prevalence of TDR in the UK has been estimated by analyzing the earliest available60
sequences from all treatment-naïve patients or from seroconverters submitted to the UK61
HIV drug resistance database matched to the national new HIV diagnoses database.3-762
The sequences are generated using Sanger capillary sequencing which has a limit of63
detection of approximately 20% of variant frequency present in the viral population.64
Using these data, the prevalence of HIV-1 TDR in the UK appeared to have peaked at65
~13% in 2002, before declining to a nadir of 6.6% in 2013.8, 9 However, the level of TDR66
has been consistently higher in men who have sex with men (MSM) and has been67
shown to be more likely in MSM infected with subtype B compared to other exposure68
groups.8, 10 The prevalence of TDR in the MSM group in the UK was estimated at 15.2%69
at its peak in 2002 before declining to its lowest level in 2013 at 7.5%.11 The MSM risk70
group also bears the highest burden of the infection accounting for 54% of new71
diagnoses and 41% of people living with HIV in the UK in 2013.1172
73
Following transmission, and in the absence of drug pressure, drug resistance mutations74
may revert to wild-type or an intermediate form due to the reduced replicative capacity of75
viruses with particular mutations.12 Some drug resistance mutations may also persist in76
latently infected cells or become compartmentalized, reappearing later in the presence of77
antiretroviral (ARV) drugs.13, 14 A number of studies have been conducted to determine78
the persistence of TDR.15-18 However, the persistence of TDR mutations has been79
shown to vary between particular types of mutations.19 In addition, some mutations may80
fall below the limit of detection of Sanger capillary sequencing and this may have an81
impact on the response to ARV therapy as these low frequency variants could reemerge82
upon initiation of therapy resulting in treatment failure.20-2283
84
The development of next generation sequencing (NGS) technologies has allowed the85
detection of low-level drug-resistant mutations present in a viral population at86
frequencies as low as 0.3%.23 Recent studies employing sensitive genotyping assays87
have shown that the prevalence of TDR can be as high as 30%.24, 25 However, several88
studies examining the clinical significance of low frequency variants on treatment89
outcome have shown that not all low frequency drug-resistant variants detected in90
treatment-naïve individuals contribute to virologic failure.2691
92
This study applied NGS to samples from patients deemed to have been infected within 693
months of sampling by the application of a recent infection testing algorithm (RITA).2794
Not only does this increase the potential to detect TDR mutations before they revert or95
are archived, as previously done using seroconvertor cohorts,4-6 but importantly96
increases the likelihood of detecting low frequency variants. Additionally, since the97
national reference laboratory in England applies this RITA to ~50% of all newly98
diagnosed HIV-1 infections, as a population level surveillance of HIV-1 incidence, these99
samples should also allow a more timely and direct measure of the prevalence of TDR100
and surveillance of circulating or emerging genotypes compared to samples from all101
newly HIV-1 diagnosed persons.102
The work was conducted as part of the National Institute for Health Research Health103
Protection Research Unit (NIHR HPRU) at University College London (UCL), a104
partnership with Public Health England (PHE) in Blood Borne and Sexually Transmitted105
Infections in collaboration with the London School of Hygiene and Tropical Medicine.106
107
METHODS108
Study population. The first plasma specimen from 442 newly HIV-1 diagnosed MSM109
sampled between July 2011 and December 2013 were analysed. This represents110
approximately 42% of all samples identified to be likely recent infections during this111
period and approximately 7% of all new infections among MSM as estimated by112
parsimonious back-calculation.8, 28, 29 All patients were treatment-naïve and identified as113
likely to be recently infected (within 6 months of infection) using RITA, which includes114
CD4+ count (>200 cells/mm3), viral load (>1,000 copies/mL) and the AxSYM HIV 1,2gO115
assay with an avidity index threshold <80% or, for samples taken between September116
and December 2013, a Limiting-antigen (LAg) avidity assay with an OD index <1.5. The117
assays differentiate likely recent from long standing infection by the strength of HIV-118
specific antibody-antigen binding.30, 31 The assays have a misclassification rate of <5%119
and samples close to the avidity or OD index cut-off values are more likely to be120
misclassified.32 Linked demographic and clinical information was extracted from the HIV121
& AIDS Reporting System (HARS) held at Public Health England (PHE).122
123
HIV-1 RNA extraction, PCR amplification and sequencing. Two hundred l of each124
sample were used to extract viral RNA using QIAamp UltraSens Virus Kit (QIAGEN) as125
per the kit instructions and the HIV-1 RNA eluted into 60L of AVE buffer. A 1.3kb126
region of the HIV pol gene (whole of protease and N-terminal half of reverse127
transcriptase; aa1-320) was amplified as previously described using 10μL of the RNA 128
extract in each PCR reaction.33 PCR products were purified using QIAQuick kit129
(QIAGEN) and quantified using both Qubit® dsDNA Broad Range and High Sensitivity130
Assay Kits and the Qubit® 2.0 Fluorometer (Life Technologies). One ng/µL of the131
amplified DNA product was used for DNA library preparation with the Nextera XT DNA132
sample prep kit (Illumina) as per the kit protocol. NGS was performed using the MiSeq133
reagent kit version 2 (Illumina).134
135
Bioinformatic analysis. A subset of the MiSeq paired-end reads from each FASTQ file136
was compared to a local database of HIV reference sequences using BLAST to identify137
an optimum reference sequence for mapping using BWA-MEM version 0.7.5. Utilising138
SAMTools the resulting files were then converted into BAM format in preparation for in-139
house developed software, QuasiBAM, which generates consensus sequences of the140
protease and reverse transcriptase regions and produces detailed information on the141
frequencies of minority variants present within each sample. These procedures were142
automated using a computational pipeline developed in-house using Python and C++.143
144
Analysis of HIV-1 subtypes, TDR and predicted drug susceptibility. HIV-1 subtypes145
were determined using four publically available HIV-1 subtyping tools, these being146
REGA HIV-1 Subtyping Tool version 3.0, SCUEAL algorithm, jumping profile Hidden147
Markov Model (jpHMM-HIV) and Context-based Modelling for Expeditious Typing148
(COMET HIV-1).34-38 When the subtyping tools were discordant, the subtype or149
circulating recombinant form (CRF) was called by manual inspection or designated as a150
URF if it could not be assigned to a particular subtype or CRF. TDR mutations were151
defined using the WHO 2009 list of surveillance drug resistance mutations.39 The drug152
susceptibility of each sample was determined using the Stanford HIV drug resistance153
database genotypic interpretation algorithm version 7.0.40154
155
Statistical analyses. Upper and lower 95% confidence intervals were determined156
using the exact binomial calculation and estimates of the additional detections provided157
by the more sensitive 2-20% test via McNemar's chi-squared test for matched data. The158
association of subtype and other demographic factors (age, geographic region, ethnicity,159
country of birth and probable country of infection) with TDR rates was determined using160
univariate analysis involving odds ratio (OR) and Chi-squared tests. Multivariable models161
were constructed to estimate the independent effects of covariates on TDR rates via162
logistic regression. Statistical analyses were carried out using Stata 13.1 software163
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp164
LP) or Microsoft Excel, with a p value <0.05 regarded as significant.165
166
RESULTS167
Characterisation of the study population. From July 2011 to December 2013, 58.1%168
(4,119 out of 7,093) of newly HIV-1 diagnosed MSM in England, Wales and Northern169
Ireland were tested using RITA by the national reference laboratory in England (Table 1).170
Of these, 26.7% (1,101) were identified as likely recent infections, of which 442 had171
sufficient residual volume and were successfully amplified by PCR and subjected to172
NGS. This represents 43.1% of all RITA positive samples during that period. Samples173
included 68 from 2011, 145 from 2012 and 229 from 2013. The median age of the study174
population was 32 years [26-40; IQR]. More than half of the newly diagnosed (51.4%)175
were from the London region; however, the proportions that were RITA tested and found176
to be recently infected and then sequenced was similar across the geographic regions177
ranging from 41.6 to 46.5%. In contrast, a higher proportion (51.2%) of samples from178
the recently infected aged over 50 years old were sequenced compared to 31.2% from179
those aged between 15 to 24 years old (Table 1).180
181
Distribution of circulating HIV-1 subtypes among recently infected MSM in the UK.182
The 442 sequences were subtyped using four web-based subtyping tools as described183
in the methods section and the assigned subtypes shown in Table 2. For 402184
sequences (91%), the results from at least three of the subtyping tools were concordant185
and the results for 425 sequences (96.2%) were concordant by at least two subtyping186
tools. The remaining sequences, where the subtyping tools disagreed or returned no187
particular assignment, were mostly complex unique recombinant forms (URFs). As188
expected, subtype B was the predominant subtype making up 75.6%. Of note, the most189
common non-B subtype group consisted of rare CRFs and URFs at 6.6%. The majority190
(27/29) of the rare CRFs/URFs were composed of a subtype B and another subtype(s)191
or CRFs (Supplementary Table 1). The subtypes of the remaining samples in order of192
abundance were subtype F1 (4.5%; n=20), CRF02_AG (4.3%; n=19), A1 (3.4%; n=15),193
C (2.3%; n=10), CRF01_AE (1.4%; n=6), CRF06_cpx (1.4%; n=6) G (0.5%; n=2) and194
CRF07_BC (0.2%; n=1).195
196
The proportion of TDR at 20% variant frequency threshold. We determined the197
proportion of TDR mutations among recently infected MSM at a variant frequency198
threshold of >20% which is equivalent to that used for Sanger capillary sequencing. At199
this threshold, TDR mutations were detected in 32 out of the 442 sequences, 7.2% [5.0 -200
10.1%; 95% CI]. By drug class, the overall TDR proportion was as follows: protease201
inhibitors (PIs: 2.7%, n=12), nucleoside reverse transcriptase inhibitors (NRTIs: 3.2%,202
n=14) and non-nucleoside reverse transcriptase inhibitors (NNRTIs: 1.6%, n=7). The203
TDR mutations detected in the 32 sequences are shown in Table 3. One sample had204
dual class resistance with three mutations, two NRTI mutations (M41L and M184V) and205
one NNRTI mutation (V106A). The remainder had single class resistance with one TDR206
mutation each except for one sample that had two NNRTI mutations (K103N and207
Y188L). The most common TDR mutations detected in each class were: L90M (n=7) for208
PIs, T215rev (n=9) for NRTIs and finally K103N (n=5) for NNRTIs (Table 3).209
210
The detection of low frequency TDR mutations between 2 and 20% mutation211
frequency thresholds. To establish the threshold for detection of low-level variants in212
our assay we determined the reproducibility of detection of variants in clinical samples.213
We compared the frequency of each codon in the pol gene amplicon of a particular214
sample with its corresponding codon in a replicate which had been processed215
independently from nucleic acid extraction to sequencing. This showed that some216
codons detected at low frequencies did not have the same percentage occurrence in the217
two independent runs and this was seen more often with variants detected at < 2%218
(Figure 1a). Furthermore, the analysis showed that if we included frequencies in the219
second replicate at plus or minus 50% of the value of the first replicate, the threshold of220
low frequency variant detection approaches 100% only at cut-off values >2% (Figure221
1b). The median depth of coverage for each replicate run was similar and high at222
15,782 [11,426-19,502; IQR] and 19,393 [15,375-22,454] for Run 1 and 2, respectively223
(Figure 1c). Thus, the threshold for low frequency variant detection in our assay was set224
at 2%.225
At the 2% variant frequency threshold, an additional 38 samples were identified to have226
TDR mutations, representing a significant increase in the overall TDR proportion at227
15.8% [13.4 – 20.6%] (McNemar's chi-squared p<0.0001). The depth of coverage at228
sites where low frequency variants were identified was very high and ranged from 7,139229
to 47,752 reads (Supplementary Table 2). By drug class, the overall TDR proportions230
when low frequency variants were included increased by 3.2-fold for PIs at 8.6%, by 1.7-231
fold for NRTIs at 5.4% and by 1.9-fold for NNRTIs at 2.9%. Low frequency variants were232
detected in 4 samples that had TDR mutations at a frequency >20%, these being: PI233
V82A + NNRTI K103N (9.7%), NNRTI K103N and Y188L + PI M46L (2.1%), NRTI234
T215S + PI M46L (11%) and PI L90M + PI D30N (5.9%). This changed the classification235
of the first 3 samples from single- to dual-class resistance. The majority of the identified236
low frequency variants were PI mutations that were detected in 26 out of 42 (62%)237
samples (Table 3 and Supplementary Table 2).238
239
Factors associated with transmitted drug resistance. Univariable analyses revealed240
that TDR was significantly associated with subtype B than non-B infections (odds ratio241
for TDR in non-B subtype infections of 0.41; 95%CI=0.19-0.85; p=0.017). This was242
mostly due to a reduced likelihood of TDR in non-B subtype infections at >20% variant243
frequency (OR=0.30; 95%CI=0.09-1.01; p=0.051 compared to OR=0.59; 95%CI=0.26-244
1.37; p=0.223 at 2-20% variant frequency). Multivariable analyses confirmed subtype as245
an independent factor associated with TDR (OR for TDR in non-B subtype infections of246
0.38; 95%CI=0.17-0.88; p=0.024). The only other factor significantly associated with247
TDR in multivariable analyses was infections that were probably acquired outside the UK248
(OR=2.64; 95%CI=1.03-6.78; p=0.044). However, this effect was slightly attenuated in249
univariable analyses (OR=2.12; 95%CI=0.93-4.83; p=0.073) and was not strongly linked250
with a particular variant frequency threshold. There was no significant association with251
age, geographic region, ethnicity and the country of birth in both univariable and252
multivariable analyses (Table 4).253
254
Predicted susceptibility of samples harbouring low frequency variants to ARVs255
recommended for first-line therapy in the UK. We investigated the predicted effect of256
the low frequency TDR mutations detected on susceptibility to the ARVs that are257
currently recommended for first-line treatment or as alternatives in the UK.41 The258
susceptibility of the samples was analysed using the Stanford HIV drug resistance259
database genotypic interpretation algorithm which assigns five different levels of drug260
susceptibility, these being: susceptible, potential resistance, low-level resistance,261
intermediate resistance and high-level resistance. Most of the TDR mutations resulted in262
low-level resistance but intermediate to high-level resistance was often associated with263
NNRTIs (Figure 2).264
At the >20% variant frequency threshold the drugs most affected were as follows: the265
NNRTIs nevirapine and efavirenz with 1.9%, the NRTI zidovudine with 2.5% and the PIs266
atazanavir and lopinavir with 1.7% of the samples showing low- to high-level resistance267
(Figure 2). The only drugs not associated with any resistance were the PI darunavir and268
the NRTI tenofovir. When the low-level frequency mutations were included we observed269
an increase in the proportion of samples with reduced susceptibility to all drugs including270
resistance to darunavir and tenofovir (Figure 2). Resistance to the NNRTIs nevirapine271
and efavirenz increased 2-fold to 4% and 3.8%, respectively, whereas that to the PIs272
lopinavir and atazanavir increased 2.3- and 2.8-fold to 4.6% and 3.8%, respectively. Of273
note, a significant proportion of the samples showed resistance to PIs and NRTIs that274
are no longer used in the UK with 2.7% of the samples showing resistance to the older275
NRTIs and PIs at >20% variant frequency threshold increasing up to 8% at >2% variant276
frequency threshold.277
278
DISCUSSION279
The data show that the proportion of TDR among recently infected MSM doubles when280
low frequency variants are taken into account from 7.2% to 15.8% at >20% and >2%281
variant frequency thresholds, respectively. This is in agreement with other studies that282
have used highly sensitive genotyping methods where the proportion of TDR among283
treatment-naïve individuals has ranged between 17-30% worldwide.20, 23, 26, 42-44 A284
majority (62%) of the low frequency variants were associated with resistance against PIs285
despite PI-associated drug resistance mutations rarely being observed among286
treatment-experienced patients failing therapy in the UK at 3.5% in 2013 compared to287
16.5% and 23.2% for NRTI and NNRTI mutations (UK HIVDRDb). It is expected that288
following transmission, drug resistance-associated variants would steadily decline and289
disappear with time in the absence of drug selective pressure. Thus, these data suggest290
either a transmission and sustained persistence of low frequency variants or a stochastic291
de novo generation of these mutations in the infected patients. For the latter, the292
mutations would be expected to be randomly distributed; however, the data show a293
predominance of particular types of low frequency variants in each drug class i.e. M46IL294
for PIs, D67GN for NRTIs and G190E for NNRTIs which are different from the most295
common drug resistance-associated mutations observed at >20% variant frequency296
threshold: L90M, T215rev and K103N, respectively. Alternatively, this could reflect the297
impact on replication fitness of individual mutations with those significantly detrimental to298
viral replication most likely to decrease rapidly in frequency in the absence of drug299
selection or it could be dependent on differences in the frequency of a given codon300
change resulting in an amino acid substitution at a particular site.301
Several studies have investigated the transmission of low frequency drug resistance302
variants.45-47 One study used ultradeep sequencing on samples from 32 recently303
infected individuals concluded that the bulk of low frequency drug resistance variants304
were either due to sequencing or de novo viral replicative errors.45 In contrast, a study305
using allele-specific PCR on samples from recently and chronically infected patients306
showed direct evidence that low frequency variants can be transmitted.46 It is possible307
that the contradictory outcomes could be a result of different experimental308
methodologies. Thus, the origins and source of these low frequency variants need309
further investigation using large well-characterized cohorts, as it has been hypothesized310
that transmitted variants are more likely to persist and establish a latent infection than de311
novo generated variants.312
Similar to previous studies of TDR prevalence in the UK the most common TDR313
mutations we identified at >20% variant frequency threshold confer resistance to drugs314
no longer used for treatment of HIV-1 infection i.e. PI L90M and NRTI T215rev.9, 48315
These mutations are likely to have been initially transmitted from ARV-experienced316
individuals further back in the transmission chain and despite absence of drug pressure317
have persisted in the population.48, 49 Interestingly, TDR mutations especially those318
present at a variant frequency greater than 20% were observed to significantly occur319
more frequently in subtype B than non-B subtypes in keeping with the notion that the320
resistance is mostly historical due to ART having been in use for longer in subtype B321
than non-B infections.322
To date, studies describing the impact of low frequency variants detected at baseline on323
treatment outcome have linked NNRTI-resistant mutations with a two-fold increase in the324
risk of virologic failure.21 One factor determined to be associated with this increased risk325
is the mutational load which is a product of the frequency of the variant and viral load.23,326
50 Viral load data were incomplete for this study but are likely to be relatively high for327
acute infections. However, we observed that the frequency of NNRTI low frequency328
variants was often higher (between 3.1% and 15.4%, and thus likely to represent a329
higher mutational load) compared to PI and NRTI variants that were mostly between 2%330
and 3% (Supplementary Table 2). Further large case-control or cohort studies are331
required to determine the impact of specific low frequency variants on treatment332
outcome.333
It has been reported that the proportion of non-B and non-C subtypes among the334
treatment-naïve MSM population in the UK has increased significantly from 5.7% to335
13.6% between 2002 and 2010.51 In this study this proportion was 23.2%, a further336
increase on the 2010 figures and in keeping with the upward trend in the proportion of337
non-B and non-C subtypes among MSM. We also show that rare CRFs/URFs were the338
most frequent non-B subtypes observed comprising ~7% of the samples. This339
proportion is likely higher than reported here as only 15% of the genome was sequenced340
and recombination could have occurred in the non-sequenced portions of the genome.341
The increase in inter-subtype recombinants could be due to increased migration from342
Africa and Eastern Europe, where they are more common, but could also reflect the343
emergence of novel recombinant forms due to an increased probability of inter-subtype344
co-infections among MSM. The latter is supported by the fact that the majority of the345
rare recombinants were composed of a subtype B and a non-B subtype or CRFs.346
A limitation of this study is the threshold for detection of low frequency variants. As347
described earlier, the low frequency variants detected in a sample could have several348
sources including real transmitted variants, variants introduced during de novo viral349
replication in vivo or laboratory artefacts introduced during RT-PCR amplification and/or350
sampling bias. Sampling bias occurs at several steps during the process: at RNA351
extraction, at RT-PCR and at DNA library preparation, all of which result in bottleneck352
effects. Laboratory artefacts and de novo viral replication errors have been shown to353
result in as high as 2% variant frequency using clinical samples from pre-ART era.52 By354
themselves RT-PCR and sequencing errors on Illumina machines have been shown to355
account for less than 0.5 to 1% of observed errors.53, 54 Our experiments using repeat356
independent amplification and sequencing of the same clinical samples showed results357
that are consistent with these previous observations with most discrepancies in variant358
calls observed at frequencies below 2%. Therefore, the 2% threshold chosen for our359
assay probably results in the ruling out of most if not all false positive variants i.e. high360
specificity, but it is likely to result in under calling of true variants i.e. less sensitivity.361
In summary, this study shows that the use of NGS can provide detailed and enhanced362
genomic information on TDR and subtype distribution in newly diagnosed HIV-1 patients363
as part of a national surveillance program. These data gathered in real time together364
with demographic data and in tandem to determination of recent infection are a useful365
extension to public health surveillance of HIV to better inform individual clinical366
prescribing practice, population-based prevention strategies and would also be useful for367
the validation of current diagnostic tools.368
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1Table 1. Demographic characteristics of UK patients included in the molecular surveillance of2
MSM recently infected with HIV, July 2011 - December 20133
Category % of rec.
infections
sequenced
New
diagnoses
RITA
tested
Recent
infections Sequenced
Geographic
Region
North 1193 712 149 62 41.6
Mid/East 914 482 114 53 46.5
London 3646 2208 657 278 42.3
South 1039 605 157 71 45.2
NI/Wales 301 112 24 10 41.7
Total 7093 4119 1101 474 43.1
Age Group
15-24 1071 659 234 73 31.2
25-34 2643 1558 459 203 44.3
35-49 2598 1493 330 158 47.9
50+ 781 409 78 40 51.2
Total 7093 4119 1101 474 43.1
4
5
1Table 2. Distribution of HIV-1 subtypes among recently infected MSM in the UK2
Subtype number % 95% CI
A1 15 3.4 [1.9-5.5]
B 334 75.6 [71.3-79.5]
C 10 2.3 [1.1-4.1]
F1 20 4.5 [2.8-6.9]
G 2 0.5 [0.06-1.6]
CRF01_AE 6 1.4 [0.5-2.9]
CRF02_AG 19 4.3 [2.6-6.6]
CRF06_cpx 6 1.4 [0.5-2.9]
CRF07_BC 1 0.2 [0.01-1.3]
Rare CRF/URF 29 6.6 [4.4-9.3]
Total 442 100 -
3
4
Table 3. Specific TDR mutations identified at different variant frequency thresholds1
PI mutations NRTI mutations NNRTI mutations
Variant frequency
threshold >20% 2-20% >20% 2-20% >20% 2-20%
Mutations (n)
L90M (7) M46IL (10) T215rev (9) D67GN (4) K103N (5) G190E (2)
M46IL (3) V32I (3) K219N (3) K70RE (2) V106A K101E
V82AL (2) D30N (3) M41L T215rev (2) Y188L Y188H
N83D (2) K70R F77L K101E K103N
I47V (2) M184V V75A Y181C
V82A (2)
L90M
N88D
I54L
I50V
Total 12 26 15a 10 8b 6
a two NRTI mutations present in one sample (M41L and M184V)2
b two NNRTI mutations present in one sample (K103N and Y188L)3
4
Table 4. Factors associated with transmitted drug resistance1
Variant
frequency
threshold Parameter
Univariate Adjusted (multivariate)
OR [CI] P-value OR [CI] P-value
>2%
(all TDR)
Infected outside UK 2.12 [0.93-4.83] 0.073 2.64 [1.03-6.78] 0.044
Born outside UK 1.26 [0.75-2.11] 0.382 0.75 [0.37-1.55] 0.442
Non-white ethnicity 1.38 [0.73-2.61] 0.315 1.63 [0.76-3.55] 0.211
Outside London 1.37 [0.81-2.33] 0.241 1.69 [0.89-3.21] 0.107
Age (15-34) 1.02 [0.61-1.70] 0.936 1.34 [0.74-2.44] 0.335
Non-B Subtype 0.41 [0.19-0.85] 0.017 0.38 [0.17-0.88] 0.024
>20%
(high frequency
TDR)
Infected outside UK 1.74 [0.57-5.38] 0.333 3.13 [0.83-11.74] 0.092
Born outside UK 0.91 [0.43-1.91] 0.802 0.43 [0.15-1.26] 0.124
Non-white ethnicity 1.12 [0.44-2.83] 0.811 1.61 [0.53-4.87] 0.398
Outside London 1.07 [0.51-2.22] 0.862 1.67 [0.70-3.95] 0.247
Age (15-34) 1.47 [0.70-3.08] 0.310 1.66 [0.72-3.83] 0.237
Non-B Subtype 0.30 [0.09-1.01] 0.051 0.30 [0.08-1.08] 0.065
2-20%
(low frequency
TDR)
Infected outside UK 2.36 [0.90-6.19] 0.082 2.08 [0.70-6.16] 0.185
Born outside UK 1.60 [0.84-3.02] 0.150 1.23 [0.52-2.91] 0.640
Non-white ethnicity 1.81 [0.87-3.79] 0.115 2.02 [0.83-4.90] 0.122
Outside London 1.51 [0.77-2.95] 0.230 1.38 [0.62-3.09] 0.427
Age (15-34) 0.94 [0.50-1.77] 0.841 1.45 [0.68-3.06] 0.337
Non-B Subtype 0.59 [0.26-1.37] 0.223 0.58 [0.22-1.52] 0.265
2
Figure Legends1
2
Figure 1. Specificity and sensitivity for detection of low frequency variants. (A)3
Correlation of translated codon frequencies, and (B) concordance of translated amino4
acid variant frequencies in protease and N-terminal half of RT (up to codon 340) for a5
clinical sample in two independent experiments. Concordance was considered at two6
levels, exact frequency (dark gray bars) or the frequency of the repeat experiment being7
within 50% of the frequency in first experiment (light gray bars). (C) Box-and-whisker8
plot showing the median, lower and upper quartile depth of coverage for the two9
independent runs, and the variability outside the lower and upper quartiles.10
11
Figure 2. Predicted drug susceptibility of the samples containing TDR among recently12
infected MSM.  The susceptibility of each sample at ≥20% and >2% mutation frequency 13
to licensed ARV drugs was predicted using the Stanford HIV drug resistance database14
genotypic interpretation algorithm. The graph shows the proportion of samples in each15
of the top three drug resistance levels used by the algorithm: low, intermediate and high16
level. The effect on drugs currently recommended for first-line treatment in the UK are17
shown individually whereas the effect on older PI and NRTI drugs that are no longer18
used in first-line therapy (other PI and NRTI) are shown together at the top of the graph.19
AZT, zidovudine; ABC, abacavir; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine,20
RPV, rilpivirine; NVP, nevirapine; EFV, efavirenz; ETR, etravirine; ATV, atazanavir; LPV,21
lopinavir; DRV, darunavir; Other PIs, fosamprenavir, indinavir, nelfinavir, saquinavir,22
tipranavir; Other NRTI, stavudine, didanosine.23
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